QM · rank #15 · 2026-10-20
IBRX
NASDAQ · $8.92B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +210.62% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +0.0% |
| Profit margin Net profit margin, trailing 12 months. | +0.0% |
| Market cap (USD) Size filter: > $500M required. | $8.92B |
| Anchor (recent) Close on 2026-09-18 | $8.48 |
| Anchor (far) Close on 2025-09-19 | $2.73 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
ImmunityBio is a commercial-stage biotechnology company focused on scaling ANKTIVA, an IL-15 receptor agonist paired with BCG for non-muscle-invasive bladder cancer and broader oncology indications.
Rationale
High 12-1 month price momentum (2.1062) is validated by fundamental acceleration, including 92% YoY Q2 2026 net product revenue growth to $50.7 million and a broader FDA label approval covering papillary NMIBC.
Material risks
- 1High operating cash burn ($141.9 million in H1 2026) relative to $357.4 million in cash reserves creates potential dilution risk from equity financing before ANKTIVA achieves cash-flow breakeven.
- 2Commercial displacement pressure from competing therapies such as Johnson & Johnson's Inlexzo/TAR-200 and operational dependency on reliable biologics and BCG supply chains.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.